

- 2 | APPROVAL OF THE
FINANCIAL STATEMENTS 2019
- 4 | WINGS
FOR THE FUTURE
- 8 | DONATIONS FOR
COVID-19 EMERGENCY

Group's continued growth

REVENUES +12.1%

THE FIRST QUARTER 2020 Continued growth

CONSOLIDATED REVENUES, in the first quarter of 2020 are € 429.2 million, up by 12.1% compared to the same period of the preceding year. International sales grew by 15.6%. They include accelerated stock building by wholesalers and pharmacies during the month of March to face the COVID-19 emergency in Italy as well as internationally, for an estimated € 20 million, which is expected to lead to de-stocking in the second quarter. Also included is revenue of € 14.7 million related to Signifor® and Signifor® LAR, which were consolidated starting 24 October 2019.

EBITDA is € 172.9 million, or 40.3% of sales (37.6% in the first quarter of 2019), an increase of 20.1%. EBITDA excludes non-recurring costs related to the COVID-19 epidemiological emergency of € 2 million, which comprise mainly donations to hospitals.

OPERATING INCOME, at 34.6% of sales, is € 148.4 million, an increase of 17.8% over the same period of the preceding year.

NET INCOME, at 25.9% of sales, is € 111.2 million, up 20.7% over the first quarter of 2019, thanks to increase in operating income, lower financial expenses and reduction of the effective tax rate. Adjusted net income, at 29.2% of sales, is € 125.2 million, an increase of 23.5% over the first quarter of 2019.

NET FINANCIAL POSITION at 31 March 2020 records a net debt of € 880.8 million compared to net debt of € 902.7 million at 31 December 2019. During the period a milestone of \$ 20.0 million was paid to Novartis following the European approval of Isturisa® and own shares were purchased for a total outlay, net of disposals for the exercise of stock options, of € 44.0 million.

SHAREHOLDERS' EQUITY is € 1,242.9 million.

"The first quarter of 2020 saw the onset of the COVID-19 pandemic in all geographical areas in which the Group operates. As we all know, restrictions were imposed on the movement of people, transport, production, commerce, most of which are still in place", stated **Andrea Recordati**, CEO. "Pharmaceutical operations were allowed to continue in order to ensure the availability of drugs for patients. While complying with all the measures necessary to ensure the health and safety of its employees, Recordati did not interrupt its production and distribution activities and adopted all necessary measures to guarantee the continued availability on the market of its products", continued Andrea Recordati. "Despite the medical emergency and the restrictions implemented in all countries, the financial results obtained in the first quarter are very positive and confirm the continued growth of the Group. **I wish to sincerely thank all the Group's employees** for the great effort and excellent job done in this difficult situation. Their professionalism, dedication and sense of responsibility, in particular **our manufacturing and distribution employees**, allowed our activities to continue in the best way possible, ensuring the uninterrupted availability of our products, many of which are for the treatment of severe, chronic diseases. We are proud of the contribution (see page 8) we have been able to provide in this emergency, also through the donations we have made to support healthcare institutions who are tirelessly and courageously committed to fighting the COVID-19 epidemic in the most affected areas".

In January the **European Commission** granted marketing authorization for the orphan medicinal product **Isturisa®** (osilodrostat), indicated for the treatment of endogenous Cushing's syndrome (CS) in adults. In March, the **Food and Drug Administration** approved Isturisa® for the treatment of patients with Cushing's disease, for whom pituitary surgery is not an option or has not been curative, in the U.S.A. Both the European Commission and the FDA confirmed the orphan drug status of Isturisa®. Also, in March, the **Japanese New Drug Application** (JNDA) was submitted to the Ministry of Health, Labour and Welfare seeking marketing approval for osilodrostat (see page 3).

As per the agreement with Novartis, in the month of February the marketing authorizations for **Signifor®** and **Signifor® LAR** in the U.S. were transferred to Recordati Rare Diseases Inc. and direct marketing of these products on this market started.

On 14 February the Company published its targets for 2020 which included, among others, net income of between € 360 and € 370 million compared to € 368.9 million in 2019 which included a non-recurring benefit of € 27 million resulting from the so-called Patent box fiscal benefit related to preceding years. The target for adjusted net income in 2020, that excludes amortization and write-down of intangible assets (except software) and goodwill, as well as non-recurring events, net of tax effects, would have been between € 408 and € 418 million, an increase over the € 383 million in 2019 according to the same definition.

Italy and all the main countries in which the Group operates continue to be impacted by restrictions to the circulation of people and provisions to support companies' economic activities have been introduced following the epidemiologic emergency due to the COVID-19 virus, declared a pandemic by the OMS in March. To face the emergency, in Italy, and subsequently also in other countries the Group has implemented all possible measures and initiatives to guarantee the supply of medicines to its patients and the safety of its employees.

Given the complex and continuously evolving situation, possible future impacts are not for the moment entirely predictable, but the Company expects EBITDA and adjusted net income to be in line with the lower limit of the target ranges announced in February.

Economic results 2019

On April 29th Recordati S.p.A.'s Annual Shareholders' Meeting approved the Group's consolidated results for the year 2019.

The financial results obtained in 2019 demonstrate the continued growth of the Group, with increased revenues and profits. All business segments, the main products as well the new business development initiatives, contributed to these results.

GROUP CONSOLIDATED REVENUE

Group consolidated revenue for 2019 is € 1,481.8 million, up 9.6% over the preceding year. International sales are € 1,194.6 million, up 10.7% and now represent 80.6% of total revenue.

As regards our Specialty and Primary Care portfolio, which represents 83.1% of revenues growing by 8.3%, Zani-dip®, Urorec® and Livazo® performed well and our self-medication products showed significant growth. During the year Reagila®, the innovative antipsychotic drug for the treatment of schi-

zophrenia, was successfully launched in the majority of Western European countries. Furthermore, the performance of our business dedicated to treatments for rare diseases was noteworthy. This business now represents 16.9% of revenues and grows by 16.3% which includes the contribution from recently acquired and licensed in products (Juxtapid® in Japan, Ledaga® in Europe and Signifor®/Signifor® LAR worldwide).

EBITDA, INCOME

Profits also showed solid growth. EBITDA, at 36.7% of sales, is € 544.0 million, an increase of 9.0% over 2018. Operating income, at 31.4% of sales, is € 465.3 million, a growth of 5.2% compared with the preceding year. Net income is € 368.9 million, an increase of 18.1%, with a margin on sales of 24.9%, significantly higher compared to that of the preceding year due to the growth of operating income and to the tax benefit provided by the so-called "Patent box" agreed with the Italian tax autho-

rities in December 2019. The total benefit is of € 35.3 million, of which € 27.0 million refers to previous years and € 8.3 million is relative to 2019. Excluding the previous years' benefit net income would be of € 341.9 million, up by 9.4% and 23.1% of revenue.

NET FINANCIAL POSITION

At 31 December 2019 the Group's net financial position records a net debt of € 902.7 million compared to net debt of € 588.4 million at 31 December 2018. During the year dividends were paid for an amount of € 190.9 million. Furthermore, an important acquisition of product rights was made and licenses obtained for new products for a total investment of around € 425 million. Shareholders' equity at 31 December 2019 is € 1,198.8 million.

The tables attached contain a summary of the 2019 financial statements which were commented in the press release issued on 18 March 2020.

FINANCIAL HIGHLIGHTS

€ thousands	2019	%	2018	%	Variazioni 2019/2018	%
Total revenue	1.481.848	100.0	1.352.235	100.0	129.613	9.6
Italy	287.289	19.4	273.197	20.2	14.092	5.2
International	1.194.559	80.6	1.079.038	79.8	115.521	10.7
EBITDA	543.967	36.7	499.079	36.9	44.888	9.0
Operating income	465.266	31.4	442.219	32.7	23.047	5.2
Net income	368.866	24.9	312.422	23.1	56.444	18.1

2019 INITIATIVES IN LINE WITH THE GROUP'S STRATEGY OF CONTINUED GROWTH AND DEVELOPMENT

FEBRUARY 2019 - Recordati signed a license agreement with Aegerion Pharmaceuticals Inc., a subsidiary of Novilion Therapeutics Inc., for the exclusive rights to commercialize **Juxtapid®**, currently approved for the treatment of homozygous familial hypercholesterolemia (HoFH), in Japan. The agreement includes a right of first negotiation for product commercialization in Japan of any potential new indications that may be developed by Aegerion. Upon signing of the agreement an upfront payment of \$ 25 million was paid to Aegerion and a milestone of \$ 5 mil-

lion was paid in June. The agreement includes commercial milestones and royalty payments. In 2018 sales of the product in Japan were of \$ 10.8 million. The addition of Juxtapid® to our portfolio of rare disease products in Japan is very important for the development of our recently established subsidiary in this country, given its potential for significant growth.

Recordati Rare Diseases, a worldwide leader in rare diseases and orphan drugs, recently announced that its strategy aimed at establishing a direct presence in the key markets across

all continents has been successfully executed. Local Recordati Rare Diseases companies are now active in North America, Latin America, Europe, Middle East and Asia Pacific. Several companies formerly operating under the name of Orphan Europe were recently renamed Recordati Rare Diseases, which is today the global brand of Recordati's organization dedicated to treatments for rare diseases and orphan drugs. Orphan Europe, founded in 1990, pioneered the development of orphan drugs in Europe and became part of Recordati in 2007.

JULY 2019 - An agreement was signed with Novartis for the acquisition of worldwide rights to **Signifor®** and **Signifor® LAR®** for the treatment of Cushing's disease and acromegaly in adult patients for whom surgery is not an option or for whom surgery has failed. Worldwide sales of Signifor® in 2019 were \$ 75 million. The agreement also covers the acquisition of worldwide rights to **Isturisa®** (osilodrostat), an investigational innovative drug for the treatment of endogenous Cushing's syndrome. The transaction was completed on 23 October 2019 and a consideration of \$ 390 million, funded by existing liquidity and new debt facilities, was paid to Novartis. Subsequently, additional milestone payments contingent upon the approval and market access of Isturisa® as well as royalties on sales of this new product, will be due.

FUTURE TARGETS

Going forward we will continue to develop the business, both by growing the existing product portfolio as well as through acquisitions of products or companies, with the objective of enhancing our presence in selected markets. The development of the segment dedicated to treatments for rare diseases and its expansion into new markets

will continue to be a priority. Our Group already makes these treatments available through its own organizations throughout Europe, in the Middle East, in the U.S.A., Canada, Mexico, in some South American countries as well as in Japan and Australia. Furthermore, we will continue to dedicate resources to research and development and strong emphasis will be placed on the enrichment of our product portfolio both through the development and launch of pipeline products as well as through the acquisition of new specialties.

SUSTAINABILITY

During 2019 a number of initiatives related to business sustainability were put in place. In this context of strong growth, of commitment to research and innovation, our Group continues to develop a structured and organic sustainability process in order to share the social, environmental and economic objectives of our operations with our stakeholders. In view of the nature of our business, sustainability has always been an integral part of the strategy of our Group, aimed at providing benefits not only to patients but also to everyone with whom and for whom we work: our shareholders, our customers, our scientific and commercial partners, our collaborators and the

local communities in which we operate.

ANNUAL SHAREHOLDERS' MEETING FURTHER RESOLUTIONS – APRIL 29TH

- Dividend for 2019 € 1.00 per share (+8.7% vs 2018), of which € 0.48 already paid in November 2018.
- Number of Board members increased from eleven to twelve. New members appointed: Francesco Balestrieri, Giorgio De Palma, Guido Guidi and Piergiorgio Peluso (independent).
- **Alfredo Altavilla** appointed non executive Chairman of the Board of Directors; Guido Guidi appointed Vice Chairman; Michaela Castelli appointed lead independent director.
- Statutory Auditors appointed for the 2020-2022 three-year period.
- EY S.p.A. appointed external auditors for the 2020-2028 nine-year period.
- Remuneration policy approved and favourable note taken of the 2019 remuneration.
- Authorization to buy-back and dispose of Recordati shares renewed


ISTURISA® (OSILODROSTAT): APPROVED IN EU, USA

Recordati recently acquired from Novartis the worldwide rights to Isturisa® (osilodrostat), a new treatment option in the management of patients with endogenous Cushing's syndrome (CS) in adults. The active substance of Isturisa® is osilodrostat, a cortisol synthesis inhibitor that works by preventing 11-beta-hydroxylase, an enzyme responsible for the final step of cortisol biosynthesis in the adrenal gland, from being created. Isturisa® will be available as 1mg, 5mg and 10mg film-coated tablets and Recordati Rare Diseases expects commercialisation to initiate in Q3 2020. Since January 2020, three important steps were achieved in this direction:

In Europe: in January, the European Commission granted marketing authorisation for the orphan medicinal product Isturisa® (osilodrostat). The EC decision also confirmed the Orphan status of Isturisa® providing 10 years of market exclusivity.

In USA: in March, the Federal Drug Administration approved Isturisa® (osilodrostat), the first and only FDA approved cortisol synthesis inhibitor for patients with Cushing's Disease. The FDA decision also confirmed the orphan status of Isturisa® providing 7 years of market exclusivity. Recordati expects Isturisa® to become commercially available in the U.S. in the second or third quarter of 2020.

In Japan: in March, the Japanese New Drug Application (JNDA) was submitted to the Ministry of Health, Labour and Welfare seeking marketing approval for osilodrostat. The JNDA for osilodrostat is primarily based on data generated by the clinical program which included Japanese patients.



THE ACTIVE SUBSTANCE OF ISTURISA® IS OSILODROSTAT, A CORTISOL SYNTHESIS INHIBITOR THAT WORKS BY PREVENTING 11-BETA-HYDROXYLASE

Wings For The Future

BY DR. ARIANNA ALBERTELLA, INDUSTRIAL PROJECT MANAGER

In 2015 Recordati launched the project **Wings for the Future** in order to be fully compliant with world anti-counterfeit directives, and more specifically United States and European (Falsified Medicines Directive) directives, which came into force earlier than in other countries to which the Group exports its products directly. To achieve this a codification and serialisation system is used for prescription drugs, which traces each individual package from the production plant and guarantees the authenticity of products through verification by the end consumer (see page 5).

The project Wings for the Future was launched by the Executive Vice President of the Group Industrial Operations area, **Roberto Teruzzi**, the project sponsor, who appointed **Antonio Magni**, Director of the Manufacturing and Quality Division, to supervise it.

In view of the complexity of the European part of the project, the Company decided to recruit **Arianna Albertella**, an Industrial Project Manager within the Manufacturing & Quality Division to co-ordinate all the design and implementation aspects of the project and to select an IT Project Manager, **Andrea Zanchetta**, from within the IT Systems Division to oversee the related IT activities.

Wings for the Future is the first project managed from our central headquarters in Milan which has involved four pharmaceutical manufacturing plants (Milan in Italy, Utebo in Spain, Saint Victor and Nanterre in France) and all the European subsidiaries of the Recordati Group as well as numerous external partners.

For every Recordati plant or subsidiary an internal project team was created composed of personnel from each department: engineering, IT, production, artwork, logistics, planning, purchasing, quality control, quality assurance, regulatory affairs, finance, legal. As a result, more than 100 people were involved.

The activities of each team were rigorously planned, co-ordinated and monitored so that progress could be measured and challenges addressed.

The progress of the project and any corrective action needed were regularly reported to and discussed by the Corporate Steering Committee composed of the directors of each function and chaired by the project sponsor.

Over fifty contract manufacturing organisations that produce for Recordati, ten marketing partners (as Market Authorisation Holders- MAH) and twelve logistics partners were involved in the implementation of the project.

Two Italian companies were selected to supply the software platforms needed to handle the complex data flows involved. One was Antares for level 4 (corporate) and level 3 (production plant) and the other was Siropack, for levels 2 and 1. Validation of the software, the interface and the infrastructures was carried out following Good Automated Manufacturing Practice (GAMP) guidelines.

The large quantity of data to be managed led to the choice of a cloud solution designed for the following:

- to be used by third parties
- to be compliant with the applicable regulations
- to be updated for compliance with the regulations
- to be easily scaled up to handle larger quantities of data

The level 4 IT System is a new software developed in order to comply with European anti-counterfeit regulations. It can be adapted to accommodate additional national regulations and was developed in close collaboration with the supplier to be in compliance with the different regulatory requirements.

Efforts were made to standardise the

serialisation equipment by installing identical machines on twenty-one packaging lines, with care taken to assess the specific requirements of all the plants involved, each with a different production bay organisation.

The serialisation project was completed according to plan and all systems went into production on schedule before the legal deadline (9th February 2019), the date set for implementation by European regulations. This ensured smooth and continuous supplies of our products to all markets with no issue.

The system is constantly monitored by all users so that they can make suggestions to improve it and minimise the impact of serialisation on the efficiency of production lines.

Difficulties did arise with some of the 60 external partners involved in the **Wings for the Future** project, but these were all solved with no interruptions to smooth and continuous supply of all products.

A common language was used across the different working groups which allowed different members of the various functions to communicate efficiently with each other, a fundamental ingredient for the success of the project. This, together with the fantastic team spirit shown in the interaction between the various members, made possible that the final objective was achieved in an outstanding way.

Implementation of the project was very complex and demanding and the challenge of serialisation was brilliantly met by Recordati thanks to the wonderful team spirit, total dedication and unquestionable professionalism of all those who took part.

ARIANNA ALBERTELLA WINS "WOMEN IN PHARMA AWARD 2019"

The International Society for Pharmaceutical Engineering (ISPE) is the largest not-for-profit professional association in the world committed to scientific, technical and regulatory advancement through the entire pharmaceutical Life Science. Founded in the USA in 1980 the ISPE now has over 18,500 members across the world in over 90 countries, and it has been present in Italy since 1992 with 500 members.

On 12th December 2019, the "ISPE Women In Pharma Graziella Molinari" prize, a prestigious accolade to reward innovative designs and excellence achieved by Italian professionals in the Life Science sector was awarded to the **Recordati Industrial Project Manager, Arianna Albertella**, "for leading 'Wings for the Future', a complex and innovative project, with passion and steadfastness, to achieve the final objective on schedule and to budget." The well-deserved prize consists of a professional training course (technical, managerial, linguistic) which the winner may choose and to which ISPE Italy will contribute €3,000.




IN THE PHOTO: THE WINNER ARIANNA ALBERTELLA, SECOND FROM LEFT

Serialisation

Serialisation in pharmaceutical companies is an inter-functional and inter-organisational commitment which requires all the parties involved to act as co-ordinated and fast-acting teams (see the project 'Wings for the Future' implemented by the Recordati Group).

The European Falsified Medicines Directive (FMD) was issued to reduce the risk and prevent the distribution of falsified medicines as well as to improve traceability and transparency. It is based on the adoption of serialisation requirements, the use of unique identifiers (**UIs**) and Anti-Tampering Devices (**ATDs**) on every medicine pack marketed in Europe.



SAFETY FEATURES AND DATAFLOW

The **Safety Features** consist of: UIs and ATDs

Unique identifiers (UIs)

These are 2D data matrix barcodes made up of four elements: product code, serial number, batch number, expiry date. The same information is also given in plain text.

Anti Tampering Devices (ATDs)

This device is used to check whether a medicine pack has been tampered with. If it has been tampered with the medicine cannot be dispensed. The type of anti-tampering device


was chosen at the discretion of the manufacturer and may be of various types: a box with various types of fastenings (sealing labels or tapes), film wrappers, blister packs.

The Safety Features dataflow is managed through a **European Hub** (European Medicines Verification System – **EMVS**) by the European Medicine Verification Organisation (EMVO) and **National Archives** (National Medicines Verification System – **NMVS**) which are all linked with each other.

The pharmaceutical manufacturers (Marketing Authorisation Holders –

MAH) are responsible for loading the unique identifiers onto the European Hub (EMVS) which in turn transmits these to the national archives of the member states where the pharmaceuticals are marketed.

Those authorised to dispense pharmaceuticals verify the authenticity of the pack when they are sold to the public by means of "decommissioning". This means deactivating the unique identifier by scanning the data matrix on the pack and at the same time sending information to the European Hub.



BENIGN PROSTATIC HYPERPLASIA (BPH)

is a non-carcinogenic (benign) enlargement of the prostate gland which becomes more common in men as they age, especially after 50 years of age. By gradually compressing the urethra and obstructing the flow of urine, **BPH** can make urination difficult and generate a whole combination of symptoms termed "lower urinary tract symptoms" (LUTs) which includes a sensation of incomplete urination or the need to empty the bladder more frequently, often at night, and urgently. Furthermore, a considerable reduction in the volume and in the force of the flow of urine may occur. As the illness progresses it may have consequences on the functioning of the bladder and require pharmacological treatment in patients defined as "moderate to serious" (e.g. based on an alpha-lithic pharma-

Efficacy of Urorec® (silodosin)

BY PIETRO MAGRONE, PHD

ceutical such as silodosin, marketed by Recordati under the brand name **Urorec®**) or even surgical resection of the prostate gland when medicinal treatment is no longer effective. It is therefore important for medicinal treatment to improve the signs and symptoms of the disorder, whether they are "moderate" or "severe", thereby making it possible to delay surgery with substantial benefit for patients.

Recently the results of trials that focus on the use of silodosin in patients defined as "serious", in order to assess the efficacy on the specific category have been published. **The research**, consisting of a special study on 543 patients enrolled in phase 3 and phase 4 clinical trials was conducted by an international team of urologists led by Prof. **Fusco** and Prof. **Mirone** from the University of Naples (with the participation, amongst others, of Prof. **Roehrborn** from the University of Texas, USA and Prof. **Cornu** from the University of Rouen, France).

The results demonstrated that silodosin in patients with severe lower urinary tract symptoms related to benign prostatic obstruction is not only able to improve symptoms and urine flow significantly more than a placebo, but that patients also draw benefit from the treatment equal to that which occurs for patients with moderate symptoms. Furthermore, for most of them (73.5%) it improved their condition from that defined as "severe" to "moderate" or "slight" at the end of the treatment, with a positive effect on the quality of their everyday life. A marked improvement in their QoL ("Quality of Life") index was observed in 62.5% of cases.

The study therefore demonstrates that silodosin can provide a clinically significant benefit for patients with BPH, including those with severe symptoms, and that its use may therefore represent a valid treatment strategy even for those waiting for surgery or wishing to delay it.

THE EUROPEAN SOCIETY FOR SEXUAL MEDICINE CONGRESS

PRAGUE, 23RD-25TH JANUARY 2020



FROM LEFT TO RIGHT:
MAURO CARBONE,
MARIA LUISA
CANEPARO, VIVIANA
BACCALARO, PIETRO
MAGRONE.

For the third year running, Recordati has sponsored the most important event in the field of sexual medicine, the **European Society for Sexual Medicine Congress (ESSM)** attended by 800 specialist physicians from all over the world.

Recordati took part in the ESSM Congress with a 15 sq m stand, the largest of those of the pharmaceutical companies there, to present **Fortacin®**, a topical spray formulation of lidocaine and prilocaine for the treatment of premature ejaculation. The product, which is already being distributed successfully in Italy, Spain, Germany and France, has therefore been brought to the attention of doctors from countries in which to-date **Fortacin®** has not yet been marketed. The large majority of urologists underlined that patients have a strong interest in this product, but at the same time they pointed out that often men go to a specialist for help with other symptoms, without mentioning disorders associated with premature ejaculation.

"Meet the Expert" sessions were organised in which **Dr. Loffi** (Careggi Hospital, Florence, Italy) illustrated the main clinical data on the efficacy of Fortacin®. This symposium "**The role of topical approach in PE: Insights from clinical practice**", chaired by **Prof. Salonia** (San Raffaele Hospital, Milan, Italy) focused on the clinical profile of **Fortacin®**. Prof Salonia confirmed the validity of the product as shown by the scientific trials he presented and from his own clinical experience stating that he found it much more effective on most of his patients if used repeatedly over time. In effect, **Fortacin®** is an easy to manage product, that is fast-acting, effective and safe and can undoubtedly be considered a valid option for the treatment of premature ejaculation.

IV Organic Acidurias International Masterclass



LISBON, 7TH-8TH FEBRUARY

Carbaglu® (carglumic acid) is an orphan drug approved in the European Union by European Commission and in the United States of America by the Food and Drug Administration (FDA) for the treatment of hyperammonemia caused by N-acetylglutamate synthase deficiency (NAGS deficiency) and that associated with the presence of the three main types of organic acidemia, rare diseases in the field of metabolic disorders.



Carbaglu® is currently the main pharmaceutical in the Recordati Rare Diseases product portfolio.

Notwithstanding the efforts some of our colleagues have been obliged to make to launch new products, most of the Recordati Rare Diseases teams and their collaborators at central headquarters have maintained a constant focus on Carbaglu®.

This dedication has produced results. During the Covid-19 period extra orders have arrived from metabolic centres and pharmaceutical distributors who forecast possible metabolic crises that hospital inpatients being treated for a Covid-19-like infection might suffer.

The IV International edition of the Organic Acidurias Masterclass was one of the latest scientific events organised by the Carbaglu® International

Marketing and Medical teams and it was held in Lisbon on 7th-8th February, just a short time before the lockdown period began.

As has occurred every year since 2018, the course was organised with the aim of involving participants and teachers in an interactive setting and of allowing participants to share clinical case studies and research projects with some of the best paediatricians specialising in rare metabolic disorders.

This year the teaching team was composed by **Prof. Sufin Yap** (Sheffield Children's Hospital, UK), **Prof. Vicente Rubio Zamora**, (Valencia Biomedicine Institute, Spain), **Dr. Ana Moráis López** (La Paz University Hospital, Madrid, Spain), **Prof. Carlo Dionisi** (Bambino Gesù Hospital, Rome, Italy, President of the



SIMMESN – Italian Society for the study of inborn metabolic diseases and neonatal screening – and **Associate Prof. Shirou Matsumoto** (Kumamoto University Hospital, Japan).

We sincerely hope that the participants achieved the aim we set ourselves, which was to improve their knowledge and possibly how they manage the treatment of their patients. In any event the doctors' participation and involvement was very wide-ranging.



FROM LEFT TO RIGHT: **MATISS MASENS** (ODS FINLAND AND BALTICS), **ANNA SAJEVA** (POLICLINICO, MILAN, ITALY), **VINCENZO GIORDANO** (INTERNATIONAL MEDICAL ADVISOR, RRD HQ), **MAR MINANO** (COMMUNICATION DIRECTOR, RRD SPAIN), **SISSI SOPRANI** (MSC, MA – INTERNATIONAL PRODUCT MANAGER, RRD HQ), **DIEGO GARCIA** (MEDICAL SCIENTIFIC LIAISON, RRD SPAIN), **JOAO ROXO**, (ODS, RRD PORTUGAL), **JOSE-RAMON PADIN** (ODS, RRD SPAIN), **PROF VICENTE RUBIO** (VALENCIA BIOMEDICINE INSTITUTE, SPAIN).

Group contribution for emergency Covid-19

On 18th March Recordati announced that the Group has allocated **€ 5 million** to contribute to the support of hospitals and health facilities in their fight against the epidemiologic emergency due to COVID-19.

"In this particularly serious moment for the whole of the European population, and not only, Recordati is actively present and committed to help doctors and patients and contribute as much as possible to halt and resolve health emergency situations in all health facilities in need" declared **Andrea Recordati**, CEO.

Furthermore, Recordati responded immediately to the appeal launched by the regional government to assist with the shortage of medicines in those facilities involved in the emergency. Requested by the Lombardy Federation of Italian dispensing chemists, Banco Farmaceutico (a charitable medicine bank) launched a publicity campaign aimed at pharmaceutical companies inviting them to do their part for the good of all. On 28th March



Banco Farmaceutico delivered **€1,290,622 of anti-viral medicines** and pharmaceuticals for pulmonary obstructive disorders (58,920 packages) donated by Recordati. These pharmaceuticals were sent to the Istituto Clinico Sant'Ambrogio of Milano and were then distributed to 75 health facilities in Lombardy.

"We hope that our donation will help give a little relief to those who are suffering from the virus and will be of some help to the doctors, nurses and health personnel in their work. We believe that to contribute to the well-being of the community and allocate a part of our funds to charitable works is not simply a company formality or a professional duty, but rather a moral imperative. It is an imperative which we feel to be an essential part of a healthy company that is not only able to grow, but also at the same time to support and develop the community in which it operates and to give pride to those who work in it" said **Andrea Recordati**.

COVID-19
AIUTACIA CURARE CHI SI È AMMALATO
Perché nessuno resti senza la speranza di guarire.
Acquisteremo farmaci e apparecchiature anche per gli ospedali più piccoli.

DONA ORA
Carta di Credito o PayPal tramite il sito www.bancofarmaceutico.org
C/C: Fondazione Banco Farmaceutico Onlus FAREINSIEME
IBAN: **IT 41 0306909606100000172069**
Causale: COVID-19 Aiutaci a curare

#FAREINSIEME

80 YEARS IN THE COMPANY

Andrea Recordati, the Chief Executive Officer, wished to personally thank two people who have dedicated their working lives to the company.



3rd February 2020 - Mrs **Giuseppina Tortorici**, born at Barletta (Bari) on 30th August 1957, joined Recordati on 1st March 1982 with the job title "Technical Department Operative". She progressed in her career over the years moving from the Packaging Department, becoming first Multifunctional Operator and then Team Leader, to the Warehouse Department. Mrs Tortorici worked at Recordati for a total of 38 years.



11th December 2019 - Mr **Ivano Tosti**, born at Vetralla (Viterbo) on 3rd June 1959, joined Recordati on 1st July 1977 with the job title "Mechanic". He then progressed in that position over the years in the Maintenance Department of the Milan plant. Mr Tosti worked at Recordati for 42 years.